Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash & Equivalents (2019 - 2025)

Benitec Biopharma's Cash & Equivalents history spans 7 years, with the latest figure at $103.6 million for Q1 2025.

  • For Q1 2025, Cash & Equivalents changed N/A year-over-year to $103.6 million; the TTM value through Mar 2025 reached $103.6 million, changed N/A, while the annual FY2024 figure was $50.9 million, 1953.53% up from the prior year.
  • Cash & Equivalents for Q1 2025 was $103.6 million at Benitec Biopharma, up from $78.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $103.6 million in Q1 2025 and bottomed at $2.5 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $16.1 million (2021), against an average of $28.5 million.
  • The largest annual shift saw Cash & Equivalents plummeted 79.45% in 2022 before it soared 1953.53% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $12.3 million in 2021, then dropped by 14.63% to $10.5 million in 2022, then skyrocketed by 94.04% to $20.4 million in 2023, then soared by 284.23% to $78.3 million in 2024, then surged by 32.32% to $103.6 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Cash & Equivalents are $103.6 million (Q1 2025), $78.3 million (Q4 2024), and $67.8 million (Q3 2024).